Nile Pharmaceuticals results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit20.84 millionEGP · +11.3% vs the same period a year earlier
Total assets863 millionEGP · +15.5% vs the same period a year earlier
Shareholders' equity452 millionEGP · +15.8% vs the same period a year earlier
Operating cash flow-203 millionEGP · −3115.9% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q1 2023 was about 20.84 million EGP, up +11.3% from 18.72 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 863 million EGP, and shareholders' equity about 452 million EGP.
- Operating cash flow for Q1 2023 was negative at 203 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit20.84 million18.72 million+11.3%
Gross profit54.31 million51.37 million+5.7%
Total assets863 million747 million+15.5%
Total liabilities411 million357 million+15.2%
Shareholders' equity452 million390 million+15.8%
Total liabilities and equity863 million747 million+15.5%
Operating cash flow-203 million6.73 million−3115.9%
Investing cash flow-1.44 million-32.72 million+95.6%
Financing cash flow195 million33.95 million+474.4%
Net change in cash-9.31 million7.95 million−217.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy